NurExone Biologic Inc. Announces Third Quarter 2025 Financial Results and Provides Corporate Update
(TSX-V:NRX),(Frankfurt:J90),(Boerse Stuttgart – Freiverkehr:J90),(Boerse Muenchen – Freiverkehr:J90),(OTC US:NRXBF),(Other OTC:NRXBF), TORONTO and HAIFA, Israel, Nov. 28, 2025 (GLOBE NEWSWIRE) — NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company“), a preclinical-stage biotechnology company pioneering exosome-based therapies for central nervous system injuries, is pleased to announce its financial results for the third quarter […]